Revolution Medicines' Rasonque Recommended for European Approval in Pancreatic Cancer

Source Summary

European regulators have recommended approval of Revolution Medicines' Rasonque for pancreatic cancer treatment, following earlier FDA clearance. The recommendation represents a significant step toward making the drug available to European patients.

Why it matters

European regulatory approval of a pancreatic cancer treatment expands access to a new therapeutic option for patients in a major market following FDA authorization.

Read the Source

• STAT News ↗